High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Ryser, Stefan ^a   Estellés, Angeles ^a   Tenorio, Edgar ^a   Kauvar, Lawrence M ^a   Gishizky, Mikhail L ^a  

^a Trellis Bioscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; HUMAN; IMMUNOLOGY; MONONUCLEAR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, KIR;

EID: 85030447292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0181464     Document Type: Article

References (21)

1. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008 Feb; 18(1):11–8 https://doi.org/10.1016/j.gde.2007.12.007 PMID: 18308558
2. Harriman WD, Collarini EJ, Sperinde GV, Strandh M, Fatholahi MM, Dutta A et al. Antibody discovery via multiplexed single cell characterization. J Immunol Methods 2009 Feb 28; 341(1–2):135–45 https://doi.org/10.1016/j.jim.2008.11.009 PMID: 19087879
3. Kauvar LM, Liu K, Park M, DeChene N, Stephenson R, Tenorio E et al. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother. 2015 Mar; 59(3):1558–68 https://doi.org/10.1128/AAC.04295-14 PMID: 25534746
4. McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S et al. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs 2014 Mar-Apr. 6(2):460–73 https://doi.org/10.4161/mabs.27760 PMID: 24492306
5. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol. 2009 Nov 15; 183(10):6338–45 https://doi.org/10.4049/jimmunol.0901373 PMID: 19841167
6. Estellés A, Woischnig AK, Liu K, Stephenson R, Lomongsod E, Nguyen D et al. A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model. Antimicrob Agents Chemother. 2016 Mar 25; 60(4):2292–301 https://doi.org/10.1128/AAC.02588-15 PMID: 26833157
7. Pardoll D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12(4), 252–264 https://doi.org/10.1038/nrc3239 PMID: 22437870
8. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017 Apr; 13(4):195–207. Epub 2017 Jan 20 https://doi.org/10.1038/nrendo.2016.205 PMID: 28106152
9. Ceeraz S, Nowak EC, Burns CM and Noelle RJ. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Research & Therapy2014 16:469
10. Hutchins NA, Unsinger J, Hotchkiss R S, Ayala A. (2014). The new normal: immuno-modulatory agents against sepsis immune suppression. Trends in Molecular Medicine, 20(4), 224–233 https://doi.org/10.1016/j.molmed.2014.01.002 PMID: 24485901
11. Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016 Feb; 56(2):157–69 https://doi.org/10.1002/jcph. 591 PMID: 26183909
12. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003 Nov; 4(11):1093–101 https://doi.org/10.1038/ni987 PMID: 14556005
13. Campbell K. S., & Purdy A. K. (2011). Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 132(3), 315–325 https://doi.org/10.1111/j.1365-2567.2010.03398.x PMID: 21214544
14. Murtaza A, Laken H, Da Silva Correia J, McNeeley P, Altobell L et al. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur. J. Cancer 2016 Dec; 69, Supplement 1:S102
15. Vey N, Karlin L, Gonçalves A, Sadot-Lebouvie S, Broussais F, Marie D et al. A phase 1 dose-escalation study of lirilumab (IPH2102, BMS-986015, LIRI), a fully human anti-KIR monoclonal antibody in patients with various hematologic (HEM) or solid (SOL) malignancies. ASCO 2015. Abstract 3065
16. Moretta A et al. Antibodies binding to receptors KIR2DL1, -2, -3 but not KIR2DS4 and their therapeutic use (2006) WO/2006/003179 PCT/EP2005/053122
17. Beerli R, Rader C. Mining human antibody repertoires. mAbs (2010) 2:4, 365–378 https://doi.org/10.4161/mabs.2.4.12187 PMID: 20505349
18. Yang D, Singh A, Wu H, Kroe-Barrett R. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. Analytical Biochemistry (2016) 508, 78–96 https://doi.org/10.1016/j.ab.2016.06.024 PMID: 27365220
19. DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YL, Lee HH et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immnol 2010 Feb 15; 184(4):1918–30
20. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015 Jan; 517(7534):386–90 https://doi.org/10.1038/ nature13848 PMID: 25363763
21. Zhu C, Anderson AC, Schubart A, Xiong H, Khoury SJ, Zheng XX et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005 Dec; 6(12):1245–52 https://doi.org/10.1038/ni1271 PMID: 16286920